Oxford BioDynamics Plc (OXBOF)
USD 0.02
(-86.0%)
USD 0.02
(-86.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.18 Million GBP | -76.97% |
| 2022 | 5.16 Million GBP | 17.0% |
| 2021 | 4.41 Million GBP | 179.1% |
| 2020 | -5.57 Million GBP | -7.31% |
| 2019 | -5.19 Million GBP | 71.56% |
| 2018 | -18.27 Million GBP | -69.32% |
| 2017 | -10.79 Million GBP | -48.3% |
| 2016 | -7.27 Million GBP | 13.7% |
| 2015 | -8.43 Million GBP | -53.42% |
| 2014 | -5.49 Million GBP | -82.17% |
| 2013 | -3.01 Million GBP | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 3.97 Million GBP | 21.12% |
| 2024 Q1 | 3.97 Million GBP | 234.57% |
| 2023 Q3 | 371 Thousand GBP | -91.86% |
| 2023 Q4 | 1.18 Million GBP | 220.49% |
| 2023 Q1 | 3.82 Million GBP | -25.98% |
| 2023 Q2 | 4.55 Million GBP | 19.29% |
| 2023 FY | 1.18 Million GBP | -76.97% |
| 2022 Q2 | 3.51 Million GBP | 25.38% |
| 2022 Q3 | 4.42 Million GBP | 26.03% |
| 2022 Q4 | 5.16 Million GBP | 16.63% |
| 2022 Q1 | 2.8 Million GBP | -36.51% |
| 2022 FY | 5.16 Million GBP | 17.0% |
| 2021 Q1 | -4.63 Million GBP | 16.92% |
| 2021 Q4 | 4.41 Million GBP | 16.78% |
| 2021 FY | 4.41 Million GBP | 179.1% |
| 2021 Q3 | 3.77 Million GBP | 183.88% |
| 2021 Q2 | -4.5 Million GBP | 2.81% |
| 2020 Q4 | -5.57 Million GBP | 2.28% |
| 2020 FY | -5.57 Million GBP | -7.31% |
| 2020 Q1 | -6.03 Million GBP | -16.01% |
| 2020 Q3 | -5.7 Million GBP | 5.34% |
| 2020 Q2 | -6.03 Million GBP | 0.0% |
| 2019 Q3 | -5.19 Million GBP | 34.58% |
| 2019 Q2 | -7.94 Million GBP | 0.0% |
| 2019 Q4 | -5.19 Million GBP | 0.0% |
| 2019 Q1 | -7.94 Million GBP | 56.53% |
| 2019 FY | -5.19 Million GBP | 71.56% |
| 2018 Q1 | -9.63 Million GBP | 10.74% |
| 2018 Q4 | -18.27 Million GBP | 0.0% |
| 2018 FY | -18.27 Million GBP | -69.32% |
| 2018 Q2 | -9.63 Million GBP | 0.0% |
| 2018 Q3 | -18.27 Million GBP | -89.68% |
| 2017 Q2 | -11.52 Million GBP | 0.0% |
| 2017 Q1 | -11.52 Million GBP | -58.26% |
| 2017 Q4 | -10.79 Million GBP | 0.0% |
| 2017 Q3 | -10.79 Million GBP | 6.29% |
| 2017 FY | -10.79 Million GBP | -48.3% |
| 2016 Q1 | -7.51 Million GBP | 10.87% |
| 2016 Q2 | -7.51 Million GBP | 0.0% |
| 2016 Q4 | -7.27 Million GBP | 0.0% |
| 2016 Q3 | -7.27 Million GBP | 3.18% |
| 2016 FY | -7.27 Million GBP | 13.7% |
| 2015 Q4 | -8.43 Million GBP | 0.0% |
| 2015 FY | -8.43 Million GBP | -53.42% |
| 2015 Q1 | 5.49 Million GBP | 0.0% |
| 2015 Q3 | -8.43 Million GBP | 0.0% |
| 2014 FY | -5.49 Million GBP | -82.17% |
| 2013 FY | -3.01 Million GBP | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.89 Million USD | 37.385% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 92.457% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -195.882% |
| SQZ Biotechnologies Company | -36.23 Million USD | 103.281% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 46.973% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 97.222% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 118.859% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -28.237% |
| Marizyme, Inc. | 18.56 Million USD | 93.597% |
| Genus plc | 190.6 Million USD | 99.376% |
| Pharming Group N.V. | 109.8 Million USD | 98.917% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -38.217% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 2.05% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -74.853% |
| ContraFect Corporation | -6.02 Million USD | 119.731% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -2.906% |
| IMV Inc. | 7.67 Million USD | 84.499% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 78.389% |
| ONE Bio Corp. | 9.04 Million USD | 86.847% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 90.816% |
| Mesoblast Limited | 55.85 Million USD | 97.871% |
| MultiCell Technologies, Inc. | 90.04 USD | -1320424.211% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 96.109% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.112% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -91.046% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -17.99% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 71.127% |
| Biomind Labs Inc. | 711.4 Thousand USD | -67.135% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 40.532% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 90.716% |
| Skye Bioscience, Inc. | -5.72 Million USD | 120.782% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -230.544% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 46.821% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -750.476% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -783.102% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 78.95% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -5884.799% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 261.994% |
| EV Biologics, Inc. | 1.36 Million USD | 13.083% |
| Q BioMed Inc. | 4.06 Million USD | 70.714% |
| GB Sciences, Inc. | 1.74 Million USD | 31.953% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 746.941% |
| CSL Limited | 10.52 Billion USD | 99.989% |
| Agentix Corp. | 37.63 Thousand USD | -3059.629% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 98.036% |
| Enzolytics Inc. | 981.65 Thousand USD | -21.122% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 6.45 Million USD | 81.569% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 276.648% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 46.003% |
| argenx SE | -2.02 Billion USD | 100.059% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 97.263% |
| HST Global, Inc. | 96.79 Thousand USD | -1128.395% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 102.529% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -476.577% |
| Halberd Corporation | 144.72 Thousand USD | -721.581% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 83.185% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 113.45% |
| Zenith Capital Corp. | 10.06 Thousand USD | -11714.388% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 56.103% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 50.168% |
| AVAX Technologies, Inc. | -5.9 Million USD | 120.142% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -622.757% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 6590.883% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -493.219% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 45.42% |
| Helix BioMedix, Inc. | -2.57 Million USD | 146.264% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 94.136% |
| Kadimastem Ltd | -253.1 Thousand USD | 569.771% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 73.412% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -490.796% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 90863.359% |
| LadRx Corporation | -2.03 Million USD | 158.385% |
| Cell Source, Inc. | 9.23 Million USD | 87.121% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 5926.147% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -87.195% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -87.195% |
| Affymax, Inc. | -5.59 Million USD | 121.244% |
| Mobile Lads Corp. | 484.23 Thousand USD | -145.543% |
| Itoco Inc. | 228.3 Thousand USD | -420.795% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -774.335% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 76.014% |
| International Stem Cell Corporation | 2.59 Million USD | 54.093% |
| CytoDyn Inc. | 20.26 Million USD | 94.132% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 183871.252% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 12928.619% |
| Qrons Inc. | 351.42 Thousand USD | -238.335% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 84.57% |
| SYBLEU INC | 473.71 Thousand USD | -150.995% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 576.324% |
| Rebus Holdings, Inc. | 305 Thousand USD | -289.836% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 73.323% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1805.052% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 45.481% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 65.376% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 86.098% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -53.895% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 195.12% |
| Neutra Corp. | 52.18 Thousand USD | -2178.345% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 147.77% |
| PureTech Health plc | -167.19 Million USD | 100.711% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 585.488% |
| IXICO plc | -4.44 Million USD | 126.752% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 91.005% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 97.832% |
| CSL Limited | 10.52 Billion USD | 99.989% |
| Cellectis S.A. | -43.81 Million USD | 102.713% |